Muse磁共振引导聚焦超声系统的可行性评估 (BreastMRgFUS)
Muse磁共振引导聚焦超声系统的可行性评价
This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer. Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care. The partial tumor ablation design will ensure that no information is lost that would impact the subject's standard of clinical care. Because current care often includes testing on the tumor, retaining a portion of viable tumor is advised by the clinical team. To ensure viable tissue confirmation, patients will be enrolled in two cohorts as described in the protocol. The investigators will use imaging correlation, histological evaluation, and subject reported outcomes to assess the safety, tolerability, and efficacy of the Muse MRgFUS System. This proposed study will adhere to the guidelines of subjects receiving a timely tumor resection after diagnosis. All subjects will undergo the definitive procedure of surgical resection per standard of care. Surgical resection cannot be delayed as a result of the ablation and should occur within 6 weeks after the decision to proceed with surgical resection. In cases where a surgery may occur outside of the 6 week window, prior approval from the external DSMC should be obtained. While MRgFUS ablation is designed to be a breast-conserving technique, the investigators will enroll patients that are undergoing any surgical resection, including both lumpectomy or mastectomy. Both surgical procedures will allow assessment of the defined primary, secondary and exploratory objectives.
研究概览
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习联系方式
- 姓名:Janna Espinosa
- 电话号码:801-585-0571
- 邮箱:janna.espinosa@hci.utah.edu
学习地点
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute at University of Utah
-
接触:
- Janna Espinosa
- 电话号码:801-585-0571
- 邮箱:janna.espinosa@hci.utah.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Subject is able to speak and understand English.
-
Female subjects 18 years of age or older with invasive breast cancer undergoing surgery
-
ECOG < 2.
-
ASA (American Society of Anesthesiologists) Physical Status Classification Scale assessment of I-II.
-
Adequate breast size for MUSE device assessed by physician prior to study enrollment.
-
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
-
Adequate Renal Function defined as an eGFR > 30 mL/min/1.73.
-
Female subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.
-
Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization (i.e. bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). The post-menopausal status will be defined as having been amenorrhoeic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:
-
Women < 50 years of age:
---Amenorrhoeic for ≥ 12 months following cessation of exogenous hormonal treatments; and
----Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.
-
Women ≥ 50 years of age:
- Amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments; or
- Had radiation-induced menopause with last menses >1 year ago; or
- Had chemotherapy-induced menopause with last menses >1 year ago.
-
Exclusion Criteria:
- Receiving other investigational agents at the time of study registration.
- Prior systemic anti-cancer therapy or any investigational therapy for neoadjuvant treatment of breast cancer.
- Prior radiation therapy to the ipsilateral breast or radiation whose field(s) encompassed the breast within which the current diagnosis of cancer is made.
- The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, or bladder or of the cervix). Low risk malignancies may be allowed after discussion with PI and medical monitor.
- Women with breast implants
- Pregnant or lactating women
- Inability to lie prone for 90 minutes as reported by patient or determined by investigator assessment.
- Known prior adverse reaction or allergy to commonly used sedatives (i.e. versed, propofol) (NCI CTCAE v5.0 Grade ≥ 3).
- Known prior adverse reaction or allergy to gadolinium contrast (NCI CTCAE v5.0 Grade ≥ 3).
- Contraindication to MRI as determined by treating physician or patient response on MRI patient history and safety questionnaire (Appendix 4)
- Medical, psychiatric, cognitive, or other conditions in the opinion of the investigator that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.
Additional Exclusion Criteria for Cohort 1 patients only
- Patient's tumor is grade 3 as determined in consultation with pathologist and treating physician.
- The amount of invasive tumor in the core biopsy specimen is small as determined in consultation with pathologist and treating physician.
- Core biopsy result is equivocal for HER2 after testing by both in situ hybridization and immunohistochemistry.
- There is doubt about the handling of the core biopsy specimen (long ischemic time, short time in fixative, different fixative), or the test is suspected by the pathologist to be negative on the basis of testing error.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Muse MRgFUS System
Subjects will undergo partial ablation of half (≤50%) of one of their tumors (if multifocal or multicentric disease) followed by surgical resection per standard of care. |
The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by type
大体时间:2 months
|
evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events |
2 months
|
|
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by severity (as defined by the NCI CTCAE, version 5.0)
大体时间:2 months
|
evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events |
2 months
|
|
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by seriousness
大体时间:2 months
|
evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events |
2 months
|
|
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by duration
大体时间:2 months
|
evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events |
2 months
|
|
frequency of adverse events (AEs), adverse device effects (ADEs), and serious adverse events (SAEs) characterized by relationship to the investigational intervention reported during and after the procedure as compared to baseline
大体时间:2 months
|
evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and incidence of device- and procedure-related adverse device effects and adverse events |
2 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate ablation efficacy by pathologic assessment
大体时间:1 month
|
estimate ablation efficacy |
1 month
|
|
Disease-free survival (DFS) as defined as the time from the date of ablation to the date of first recurrence or death from any cause
大体时间:5 years
|
estimate disease-free survival (DFS) at 5 years post ablation |
5 years
|
|
Overall survival (OS) as defined as the time from registration until death from any cause
大体时间:5 years
|
estimate overall survival in this study population at 5 years post ablation |
5 years
|
|
Evaluate ablation efficacy by MRI treatment assessment metrics of thermal dose
大体时间:1 month
|
estimate ablation efficacy |
1 month
|
|
Evaluate ablation efficacy by T1-weighted non-perfused volume.
大体时间:1 month
|
estimate ablation efficacy |
1 month
|
|
Evaluate how heat-induced pathways effect associations between vascular organization and immune cell infiltration.
大体时间:5 years
|
Analysis via bulk RNA sequencing data |
5 years
|
合作者和调查者
调查人员
- 首席研究员:Cindy Matsen, MD、Huntsman Cancer Institute
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.